Golden-vice pharmaceutical: Fuzhou Meifeng Pharmaceutical Factory's hydrolyzed protein injection obtained re-registration approval.

On August 20, 2025, Jingling Pharmaceutical announced that its subsidiary Fuzhou Meifeng Pharmaceutical Factory recently received the approval notice for the re-registration of hydrolyzed protein injection issued by the Fujian Provincial Drug Administration. The drug acceptance number is CYHZ2514512 Min, with a specification of 500ml:25g, and it is classified as a chemical drug. Due to long-term non-production, the resumption of production requires an on-site inspection application to the provincial drug regulatory authority. It can only be marketed after passing the inspection and sampling inspection. Hydrolyzed protein injection is used for severe amino acid deficiency and hypoalbuminemia. Re-registration is beneficial for the resumption of drug production and sales, but it has no significant impact on recent performance. The production and sales of drugs are subject to uncertainty due to factors such as policies and the market, and investors are reminded to pay attention to risks.